about
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristicsPathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancerZinc-based fixative improves preservation of genomic DNA and proteins in histoprocessing of human tissues.HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs.Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial.Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.Time to abandon testing for microscopic haematuria in adults?The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-GuérinRole of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node.Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies.Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.Guidelines on bladder cancer.The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancerA second-look TUR in T1 transitional cell carcinoma: why?Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER StatusAdvances in intravesical therapy of urinary bladder cancer.Lymph node staging in prostatic carcinoma revisited.Low-grade Ta (noninvasive) urothelial carcinoma of the bladder.Non-muscle-invasive bladder cancer: a vision for the future.Breast cancer survival in the US and Europe: a CONCORD high-resolution study.Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapyThe combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Grading breast cancer tissues using molecular portraits.The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.Bladder tumours: time for a paradigm shift?An overview on preclinical and clinical experiences with photodynamic therapy for bladder cancer.Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus.Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrencesSecond-look resection for primary stage T1 bladder cancer: a population-based study.
P50
Q24595882-40E6821E-D44E-48B2-962D-0BE428F2FB4EQ28255916-B7BEC035-D2B5-4FF1-8CBD-8F347FF63661Q31146482-0E665EE7-D8BA-401D-8591-2C5C2D1BC461Q33201126-B1828C3A-7ED7-4538-B45B-1C120B47840AQ33350663-4F16FD09-3703-440F-A64D-9F9AF36FAEC3Q33368290-594031C6-7A5C-4664-81A4-A8B4D79490DFQ33438009-051A52F1-A4C6-418A-BC30-AFD0BBC86D15Q33721258-1490921D-DFDB-4005-89C5-99BBC30E7353Q33726400-B5CDA5F1-2727-40C4-BE12-66512DF26E72Q33726716-64D00805-49FE-4058-B961-1F7F15FAEF09Q33814654-6428AB85-6F78-4058-B528-5A38963D28A1Q33887291-EFE6B6CE-6511-48CC-BA49-C82C129BAF7DQ34075838-E1238F60-097F-42E7-8DD3-A4F2D543D5D7Q34155929-02666282-1E74-47F7-820A-5364F7A1D886Q34307779-72F1DBCA-B564-445C-8B75-4F72D5B0C41FQ34515619-82D2F999-1433-48BF-9E52-690193903B5BQ34658794-182A39E4-326D-4145-A575-C3B2F0D17547Q34695710-729EB46B-1459-4601-8431-C61E817E4C22Q35064038-EB3C2095-6C13-4574-82FC-32694BEB6A83Q35184816-4F1B40A0-4235-4E65-981F-67FBC187A2FFQ35214846-4D436140-E640-4352-A8FA-3F05690E1093Q35744852-8DE0F748-419A-4E32-88C3-AF6A3DC17C27Q35757521-5AED2337-5EAF-4CED-8A46-36A79F072CD3Q35921287-BF4E9BEF-FDA8-4EC7-B403-0AB5BDE5E553Q35987762-E2C190DB-E005-4EE6-970F-C491BFA19231Q36258503-8A391C2D-D713-42AC-89F6-70E6E1B65F03Q36363229-810FE757-537C-4295-84C9-88BA72CE5501Q36378757-D785AAF1-50BA-460E-BF3B-1F65A41C980AQ36446450-AAAED3B8-B42E-40DF-9445-EFD7C9C7DCF4Q36678711-D443BEBF-2763-477B-B681-37D1FF17CF3DQ36732425-F3CF3918-FFE3-4FD7-890B-BA92D779C7D1Q37388984-B2670D50-37CC-49AE-9164-25C7F3105DF8Q37647214-77E604F3-472F-491E-9F1E-A7C7217F96FEQ37684092-238BED19-568B-4AE1-B061-37526A143485Q37868801-E349C62C-1079-4DEC-BBAC-E5A73DE0351FQ37920001-4F85C589-4E2E-480F-B4C4-5B5DBA471E55Q38287034-72BE9170-87C9-4E50-8E36-FB67BD2E290EQ38384962-26E29960-7446-4491-AB37-22DEF602893DQ38394007-CB438A25-50FC-4B2F-AEC1-316555EFC376Q38842782-3D04C7B7-98D2-4EA1-BEC8-708D7A4AD1A5
P50
description
researcher ORCID ID = 0000-0001-8572-9957
@en
wetenschapper
@nl
name
Per-Uno Malmström
@ast
Per-Uno Malmström
@en
Per-Uno Malmström
@nl
type
label
Per-Uno Malmström
@ast
Per-Uno Malmström
@en
Per-Uno Malmström
@nl
altLabel
per-uno malmström
@en
prefLabel
Per-Uno Malmström
@ast
Per-Uno Malmström
@en
Per-Uno Malmström
@nl
P106
P31
P496
0000-0001-8572-9957